Parathyroid cancer: Etiology, clinical presentation and treatment

Anticancer Research

Volumn 26, Issue 6 C, 2006, Pages 4803-4807

  Lumachi, Franco ^a   Basso, Stefano M M ^a   Basso, Umberto ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Bisphosphonates; Hypercalcemia; Parathyroid cancer; Parathyroid carcinoma; Primary hyperparathyroidism; Review

Indexed keywords

BLEOMYCIN; CALCITONIN; CARBOPLATIN; CINACALCET; CLODRONIC ACID; CYCLIN D1; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; KI 67 ANTIGEN; LOMUSTINE; METHOTREXATE; PACLITAXEL; PAMIDRONIC ACID; PARATHYROID HORMONE; PROTEIN P53; ZOLEDRONIC ACID;

CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL FEATURE; GENE; GENE MUTATION; HORMONE RELEASE; HUMAN; HYPERCALCEMIA; METASTASIS; PARATHYROID CARCINOMA; PATHOGENESIS; PRAD1 GENE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

HUMANS; PARATHYROID NEOPLASMS;

EID: 33845960106     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Lumachi F, Ermani M, Marino F et al: Relationship of AgNOR counts and nuclear DNA content to survival in patients with parathyroid carcinoma. Endocrine-Relat Cancer 11: 563-569, 2004.
2. Iacobone M, Lumachi F and Favia G: Up-to-date on parathyroid carcinoma: analysis of an experience of 19 cases. J Surg Oncol 88: 223-228, 2004.
3. Obara T and Fujimoto Y: Diagnosis and treatment of patients with parathyroid carcinoma. An update and review. World J Surg 75: 738-744, 1991.
4. Shane E: Clinical review 122: parathyroid carcinoma. J Clin Endocrinol Metab 86: 485-493, 2001.
5. Hundahl SA, Fleming ID, Fremgen AM et al: Two hundred eighty-six cases of parathyroid carcinoma treated in the US between 1985-1995. Cancer 86: 538-544, 1999.
6. Rawat N, Khetan N, Williams DW et al: Parathyroid carcinoma. Br J Surg 92: 1345-1353, 2005.
7. Mittendorf EA and McHenry CR: Parathyroid carcinoma. J Surg Oncol 89: 136-142, 2005.
8. Cetani F, Pardi E, Borsari S et al: Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab 89: 5583-5591, 2004.
9. Hunt JL, Carty SE, Yim JH et al: Allelic loss in parathyroid neoplasia can help characterize malignancy. Am J Surg Pathol 29: 1049-1055, 2005.
10. Lumachi F and Basso SMM: Apoptosis: life through planned cellular death. Regulating mechanism, control systems and relations with thyroid diseases. Thyroid 12: 27-34, 2002.
11. Szende B, Farid P, Vegso G et al: Apoptosis and p53, Bcl-2 and Bax gene expression in parathyroid glands of patients with hyperparathyroidism. Pathol Oncol Res 10: 92-103, 2004.
12. Favia G, Lumachi F, Polistina F et al: Parathyroid carcinoma: sixteen new cases and suggestions for correct management. World J Surg 22: 1225-1230, 1998.
13. Koea JB and Shaw JH: Parathyroid cancer: biology and management. Surg Oncol 8: 155-165, 1999.
14. Rodgers SE and and Perrier ND: Parathyroid carcinoma. Curr Opin Oncol 18: 16-22, 2006.
15. Messerer CL, Bugis SP, Baliski C et al: Normocalcemic parathyroid carcinoma: an unusual clinical presentation. World J Surg Oncol 4: 10-14, 2006.
16. Lee JE: Predicting the presence of parathyroid carcinoma. Ann Surg Oncol 12: 1-2, 2005.
17. DeLellis RA: Parathyroid carcinoma. An overview. Adv Anat Pathol 12: 53-61, 2005.
18. Lumachi F, Ermani M, Marino F et al: PCNA-LI, Ki-67 immunostaining, p53 activity and histopathological variables in predicting the clinical outcome in patients with parathyroid carcinoma. Anticancer Res 26: 1305-1308, 2006.
19. Lumachi F, Zucchetta P, Marzola MC et al: Advantages of combined technetium-99m-sestamibi scintigraphy and high-resolution ultrasonography in parathyroid localization: comparative study in 91 patients with primary hyperparathyroidism. Eur J Endocrinol 143: 755-760, 2000.
20. Lumachi F, Ermani M, Basso S et al: Localization of parathyroid tumors in the minimally invasive era: which technique should be chosen? Population-based analysis of 253 patients undergoing parathyroidectomy and factors affecting parathyroid gland detection. Endocrine-Relat Cancer 8: 63-69, 2001.
21. Lumachi F, Tregnaghi A, Zucchetta P et al: Technetium-99m sestamibi scintigraphy and helical CT together in patients with primary hyperparathyroidism: a prospective clinical study. Brit J Radiol 77: 100-103, 2004.
22. Cheah WK, Rauff A, Lee KO et al: Parathyroid carcinoma: a case series. Ann Acad Med 34: 443-446, 2005.
23. Obara T, Okamoto T, Kanbe M et al: Functioning parathyroid carcinoma: clinicopathological features and rational treatment. Semin Surg Oncol 13: 134-141, 1997.
24. Chiofalo MG, Scognamiglio F, Losito S et al: Huge parathyroid carcinoma: clinical considerations and literature review. World J Surg Oncol 3: 39-45, 2005.
25. Clayman GL, Gonzales HE, El-Naggar A et al: Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer 100: 900-905, 2004.
26. Kebebew E, Arici C, Duh QY et al: Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg 136: 878-885, 2001.
27. Iacobone M, Ruffolo C, Lumachi F et al: Results of iterative surgery for persistent and recurrent parathyroid carcinoma. Langenbecks Arch Surg 390: 385-290, 2005.
28. Chow E, Tsang RW, Brierley JD et al: Parathyroid carcinoma-The Princess Margaret Hospital Experience. Int J Radiation Oncology Biol Phys 41: 569-572, 1998.
29. Munson ND, Foote RL, Norhcutt RC et al: Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer 98: 2378-2384, 2003.
30. Busaidy NL, Jimenez C, Habra MA et al: Parathyroid carcinoma: a 22-year experience. Head Neck 26: 716-726, 2004.
31. Al-Sobhi S, Ashari LH and Ingemansson S: Detection of metastatic parathyroid carcinoma with Tc-99m sestamibi imaging. Clin Nucl Med 24: 21-23, 1999.
32. Palestro CJ, Tomas MB and Tronco GG: Radionuclide imaging of the parathyroid glands. Semin Nucl Med 35: 266-276, 2005.
33. Kleinpeter KP, Lovato JF, Clark PB et al: Is parathyroid carcinoma indeed a lethal disease? Ann Surg Oncol 12: 260-266, 2005.
34. Neumann DR, Esselstyn CB and Kim EY: Recurrent postoperative parathyroid carcinoma: FDG-PET and sestamibi-SPECT findings. J Nucl Med 57: 2000-2001, 1996.
35. Arslan N and Rydzewski B: Detection of a recurrent parathyroid carcinoma with FDG positron emission tomography. Clin Nucl Med 27: 221-222, 2002.
36. Sandelin K, Auer G, Bandeson L et al: Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surgery 16: 724-735, 1992.
37. Obara T, Okamoto T, Ito Y et al: Surgical and medical management of patients with pulmonary metastases from parathyroid carcinoma. Surgery 114: 1040-1048, 1993.
38. Vainas IG, Tsilikas C, Grecu A et al: Metastatic parathyroid carcinoma (mPCa): natural history and treatment of a case. J Exp Clin Cancer Res 16: 429-432, 1997.
39. Koyano H, Shishiba Y, Shimizu T et al: Successful treatment by surgical removal of bone metastasis producing PTH: new approach to the management of metastatic parathyroid carcinoma. Intern Med 33: 697-702, 1994.
40. Wynne AG, van Heerden J, Carney JA et al: Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore) 71: 197-205, 1992.
41. Chahinian AP, Holland JF, Nieburgs HE et al: Metastatic nonfunctioning parathyroid carcinoma: ultrastructural evidence of secretory granules and response to chemotherapy. Am J Med Sci 282: 80-84, 1981.
42. Calandra DB, Cheifec G, Foy BK et al: Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery 96: 1132-1137, 1984.
43. Bukowsky RM, Sheeler L, Cunningham J et al: Successful combination chemotherapy for metastatic parathyroid carcinoma. Arch Intern Med 144: 399-400, 1984.
44. Hakaim AG and Esselstyn CB Jr: Parathyroid carcinoma: 50-year experience at The Cleveland Clinic Foundation. Cleve Clin J Med 60: 331-335, 1993.
45. Betea D, Bradwell AR, Harvey TC et al: Hormonal and Biochemical Normalization and Tumor Shrinkage Induced by Anti-Parathyroid Hormone Immunotherapy in a Patient with Metastatic Parathyroid Carcinoma. J Clin Endocrinol Metabol 89: 3413-3420, 2004.
46. Schott M, Feldkamp J, Schattenberg D et al: Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. Eur J Endocrinol 142: 300-306, 2000.
47. Shane E, Jacobs T, Siris E et al: Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate. Am J Med 72: 939-944, 1982.
48. Jacobs T, Gordon A, Gundberg C et al: Neoplastic hypercalcemia: physiologic response to intravenous etidronate. Am J Med 82: 42-52, 1987.
49. Mann K: Oral biphosphonate therapy in metastatic parathyroid carcinoma. Lancet 1: 101-102, 1985.
50. Newrick PG, Braatvedt GD, Webb AJ et al: Prolonged remission of hypercalcemia due to parathyroid carcinoma with pamidronate. Postgrad Med J 70: 231-232, 1994.
51. Major P, Lortholary A, Hon J et al: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19: 558-567, 2001.
52. Au W: Calcitonin treatment of hypercalcemia due to parathyroid carcinoma: synergistic effect of prednisone on long term treatment of hypercalcemia. Arch Intern Med 135: 1549-1597, 1975.
53. Nemeth EF, Steffey ME, Hammerland LG et al: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95: 4040-4045, 1998.
54. Peacock M, Bilexikian JP, Klassen PS et al: Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90: 135-141, 2005.
55. Collins MT, Skarulis MC, Bilezikian JP et al: Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83: 1083-1088, 1998.
56. Body JJ, Facon T, Coleman RE et al: A study of the biological receptor activator of nuclear factor-kappa B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12: 1221-1228, 2006.